-
The Merck integrase inhibitor, raltegravir, was studied in two identical trials in different geographic locations to evaluate its safety and efficacy vs placebo in combination with optimized background therapy in patients infected with 3-drug class-resistant (3DCR) HIV-1.
-
Nucleic acid tests (NAA) for the diagnosis of pulmonary tuberculosis (TB) have had FDA approval for more than a decade, but their use has been limited, at least in part because of a frequent lack of availability in local laboratories.
-
-
In this issue: FDA warning on topical anesthetics; antipsychotics increase sudden cardiac death; the step up vs step down debate; treating pain, fatigue, mood, and sleep in fibromyalgia; FDA Actions.
-
Influenza activity has been relatively low thus far in the 2008-2009 season in the United States. However, of the influenza viruses isolated and tested to date, there is significant resistance among the influenza A (H1N1) viruses to the antiviral oseltamivir.
-
For this study, 12,765 patients from the large French Hospital Database for HIV with CD4+ lymphocyte counts < 200 cells/uL who received cART during 2000-2005 were selected.
-
A randomized, double-blind, placebo-controlled trial conducted in England among 687 children 10-60 months of age with acute virus-associated wheezing compared a five-day course of oral prednisolone (10 m once a day for children 10-24 months of age and 20 mg once a day for older children) with placebo.
-
FDA approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible gram-positive organisms including Staphylococcus aureus (MRSA and MSSA), Streptococcus agalactiae, Streptococcus anginosus group, Streptococcus pyogenes, and Enterococcus faecalis.
-
The first article summarizes the practical aspects of choosing an antibiotic in a patient with a reported drug allergy. The second describes the presence of K103 resistant virus in CSF but not in plasma.
-
A protease-inhibitor-based regimen containing lopinavir-ritonavir provided more durable antiviral efficacy than a similar regimen containing nelfinavir in treatment-naïve HIV-infected patients.